Post-synthetic regulation of HS structure: The yin and yang of the Sulfs in cancer

Frontiers in Oncology

Volumn 4 JAN, Issue , 2014, Pages

  Vivès, Romain R ^a,b,c   Seffouh, Amal ^a,b,c   Lortat Jacob, Hugues ^a,b,c  

^a UNIV GRENOBLE ALPES   (France)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

^c CEA GRENOBLE   (France)

Author keywords

Cancer; Glycosaminoglycan; Heparan sulfate; Interaction; Signaling; Sulfatase

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN; BORTEZOMIB; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 4; FIBRONECTIN; FRIZZLED PROTEIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; KERATINOCYTE GROWTH FACTOR; MUPARFOSTAT; OKN 007; PLATELET DERIVED GROWTH FACTOR; PROTEOGLYCAN; SCATTER FACTOR; SONIC HEDGEHOG PROTEIN; STROMAL CELL DERIVED FACTOR 1; SULFATASE; SULFOTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

CANCER PROGNOSIS; DEVELOPMENT; DRUG TARGETING; ENZYME ACTIVITY; ENZYME STRUCTURE; HOMEOSTASIS; HUMAN; LIGAND BINDING; NEOPLASM; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84893700992     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00331     Document Type: Review

References (116)

1. Nathan C, Sporn M. Cytokines in context. J Cell Biol (1991) 113(5):981-6. doi: 10.1083/jcb.113.5.981
2. Ruoslahti E, Yamaguchi Y, Hildebrand A, Border WA. Extracellular matrix/growth factor interactions. Cold Spring Harb Symp Quant Biol (1992) 57:309-15. doi:10.1101/SQB.1992.057.01.035
3. Taipale J, Keski-Oja J. Growth factors in the extracellular matrix. FASEB J (1997) 11(1):51-9.
4. Flaumenhaft R, Rifkin DB. The extracellular regulation of growth factor action. Mol Biol Cell (1992) 3(10):1057-65. doi:10.1091/mbc.3.10.1057
5. Lander AD. Proteoglycans: master regulators of molecular encounter? Matrix Biol (1998) 17(7):465-72. doi:10.1016/S0945-053X(98)90093-2
6. Park PW, Reizes O, Bernfield M. Cell surface heparan sulfate proteoglycans: selective regulators of ligand-receptor encounters. J Biol Chem (2000) 275(39):29923-6. doi:10.1074/jbc.275.5.3057
7. Hynes RO, Naba A. Overview of the matrisome -an inventory of extracellular matrix constituents and functions. Cold Spring Harb Perspect Biol (2012) 4(1):a004903. doi:10.1101/cshperspect.a004903
8. Ramirez F, Rifkin DB. Cell signaling events: a view from the matrix. Matrix Biol (2003) 22(2):101-7. doi:10.1016/S0945-053X(03)00002-7
9. Rozario T, DeSimone DW. The extracellular matrix in development and morphogenesis: a dynamic view. Dev Biol (2010) 341(1):126-40. doi:10.1016/j.ydbio.2009.10.026
10. Iozzo RV, Zoeller JJ, Nystrom A. Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells (2009) 27(5):503-13. doi:10.1007/s10059-009-0069-0
11. Gallagher JT. The extended family of proteoglycans: social residents of the pericellular zone. Curr Opin Cell Biol (1989) 1(6):1201-18. doi:10.1016/S0955-0674(89)80072-9
12. Sarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol (2011) 3(7):a004952. doi:10.1101/cshperspect.a004952
13. Dreyfuss JL, Regatieri CV, Jarrouge TR, Cavalheiro RP, Sampaio LO, Nader HB. Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. An Acad Bras Cienc (2009) 81(3):409-29. doi:10.1590/S0001-37652009000300007
14. Lortat-Jacob H. The molecular basis and functional implications of chemokine interactions with heparan sulphate. Curr Opin Struct Biol (2009) 19(5):543-8. doi:10.1016/j.sbi.2009.09.003
15. Salanga CL, Handel TM. Chemokine oligomerization and interactions with receptors and glycosaminoglycans: the role of structural dynamics in function. Exp Cell Res (2011) 317(5):590-601. doi:10.1016/j.yexcr.2011.01.004
16. Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 14(3):166-80. doi:10.1038/nrm3528
17. Whisstock JC, Pike RN, Jin L, Skinner R, Pei XY, Carrell RW, et al. Conformational changes in serpins: II. The mechanism of activation of antithrombin by heparindagger. J Mol Biol (2000) 301(5):1287-305. doi:10.1006/jmbi.2000.3982
18. Duchesne L, Octeau V, Bearon RN, Beckett A, Prior IA, Lounis B, et al. Transport of fibroblast growth factor 2 in the pericellular matrix is controlled by the spatial distribution of its binding sites in heparan sulfate. PLoS Biol (2012) 10(7):e1001361. doi:10.1371/journal.pbio.1001361
19. Belov AA, Mohammadi M. Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 5(6):a015958. doi:10.1101/cshperspect.a015958
20. Harrison CA, Al-Musawi SL, Walton KL. Prodomains regulate the synthesis, extracellular localisation and activity of TGF-beta superfamily ligands. Growth Factors (2011) 29(5):174-86. doi:10.3109/08977194.2011.608666
21. Rueda P, Richart A, Recalde A, Gasse P, Vilar J, Guerin C, et al. Homeostatic and tissue reparation defaults in mice carrying selective genetic invalidation of CXCL12/proteoglycan interactions. Circulation (2012) 126(15):1882-95. doi:10.1161/CIRCULATIONAHA.112.113290
22. van Wijk XM, van Kuppevelt TH. Heparan sulfate in angiogenesis: a target for therapy. Angiogenesis (Forthcoming 2014).
23. Kreuger J, Kjellen L. Heparan sulfate biosynthesis: regulation and variability. J Histochem Cytochem (2012) 60(12):898-907. doi:10.1369/0022155412464972
24. Kreuger J, Salmivirta M, Sturiale L, Gimenez-Gallego G, Lindahl U. Sequence analysis of heparan sulfate epitopes with graded affinities for fibroblast growth factors 1 and 2. J Biol Chem (2001) 276(33):30744-52. doi:10.1074/jbc. M102628200
25. Pye DA, Vives RR, Hyde P, Gallagher JT. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology (2000) 10(11):1183-92. doi:10.1093/glycob/10.11.1183
26. Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library. J Biol Chem (2004) 279(13):12346-54. doi:10.1074/jbc. M313523200
27. Kreuger J, Jemth P, Sanders-Lindberg E, Eliahu L, Ron D, Basilico C, et al. Fibroblast growth factors share binding sites in heparan sulphate. Biochem J (2005) 389(1):145-50. doi:10.1042/BJ20042129
28. Izvolsky KI, Shoykhet D, Yang Y, Yu Q, Nugent MA, Cardoso WV. Heparan sulfate-FGF10 interactions during lung morphogenesis. Dev Biol (2003) 258(1):185-200. doi:10.1016/S0012-1606(03)00114-3
29. Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. J Biol Chem (1994) 269(15):11216-23.
30. Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M. Structural features in heparin that interact with VEGF165 and modulate its biological activity. Glycobiology (1999) 9(7):705-11. doi:10.1093/glycob/9.7.705
31. Feyzi E, Lustig F, Fager G, Spillmann D, Lindahl U, Salmivirta M. Characterization of heparin and heparan sulfate domains binding to the long splice variant of platelet-derived growth factor A chain. J Biol Chem (1997) 272(9):5518-24. doi:10.1074/jbc.272.9.5518
32. Mahalingam Y, Gallagher JT, Couchman JR. Cellular adhesion responses to the heparin-binding (HepII) domain of fibronectin require heparan sulfate with specific properties. J Biol Chem (2007) 282(5):3221-30. doi:10.1074/jbc. M604938200
33. Zhang S, Condac E, Qiu H, Jiang J, Gutierrez-Sanchez G, Bergmann C, et al. Heparin-induced leukocytosis requires 6-O-sulfation and is caused by blockade of selectin-and CXCL12 protein-mediated leukocyte trafficking in mice. J Biol Chem (2012) 287(8):5542-53. doi:10.1074/jbc. M111.314716
34. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem (1993) 268(32):23906-14.
35. Ishihara M, Takano R, Kanda T, Hayashi K, Hara S, Kikuchi H, et al. Importance of 6-O-sulfate groups of glucosamine residues in heparin for activation of FGF-1 and FGF-2. J Biochem Tokyo (1995) 118(6):1255-60.
36. Pye DA, Vives RR, Turnbull JE, Hyde P, Gallagher JT. Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem (1998) 273(36):22936-42. doi:10.1074/jbc.273.36.22936
37. Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA, Gallagher JT. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem (1998) 273(1):51-7. doi:10.1074/jbc.273.1.51
38. Delcommenne M, Klingemann HG. Detection and characterization of syndecan-1-associated heparan sulfate 6-O-sulfated motifs overexpressed in multiple myeloma cells using single chain antibody variable fragments. Hum Antibodies (2012) 21(1-2):29-40. doi:10.3233/HAB-2012-0259
39. Habuchi H, Tanaka M, Habuchi O, Yoshida K, Suzuki H, Ban K, et al. The occurrence of three isoforms of heparan sulfate 6-O-sulfotransferase having different specificities for hexuronic acid adjacent to the targeted N-sulfoglucosamine. J Biol Chem (2000) 275(4):2859-68. doi:10.1074/jbc.275.4.2859
40. Smeds E, Habuchi H, Do AT, Hjertson E, Grundberg H, Kimata K, et al. Substrate specificities of mouse heparan sulphate glucosaminyl 6-O-sulphotransferases. Biochem J (2003) 372(2):371-80. doi:10.1042/BJ20021666
41. Dhoot GK, Gustafsson MK, Ai X, Sun W, Standiford DM, Emerson CP Jr. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. Science (2001) 293(5535):1663-6. doi:10.1126/science.293.5535.1663
42. Ai X, Do AT, Kusche-Gullberg M, Lindahl U, Lu K, Emerson CP Jr. Substrate specificity and domain functions of extracellular heparan sulfate 6-O-endosulfatases, QSulf1 and QSulf2. J Biol Chem (2006) 281(8):4969-76. doi:10.1074/jbc. M511902200
43. Braquart-Varnier C, Danesin C, Clouscard-Martinato C, Agius E, Escalas N, Benazeraf B, et al. A subtractive approach to characterize genes with regionalized expression in the gliogenic ventral neuroepithelium: identification of chick sulfatase 1 as a new oligodendrocyte lineage gene. Mol Cell Neurosci (2004) 25(4):612-28. doi:10.1016/j.mcn.2003.11.013
44. Morimoto-Tomita M, Uchimura K, Werb Z, Hemmerich S, Rosen SD. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. J Biol Chem (2002) 277(51):49175-85. doi:10.1074/jbc. M205131200
45. Ohto T, Uchida H, Yamazaki H, Keino-Masu K, Matsui A, Masu M. Identification of a novel nonlysosomal sulphatase expressed in the floor plate, choroid plexus and cartilage. Genes Cells (2002) 7(2):173-85. doi:10.1046/j.1356-9597.2001.00502.x
46. Hanson SR, Best MD, Wong CH. Sulfatases: structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed Engl (2004) 43(43):5736-63. doi:10.1002/anie.200300632
47. Dierks T, Schmidt B, von Figura K. Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. Proc Natl Acad Sci U S A (1997) 94(22):11963-8. doi:10.1073/pnas.94.22.11963
48. Frese MA, Milz F, Dick M, Lamanna WC, Dierks T. Characterization of the human sulfatase Sulf1 and its high affinity heparin/heparan sulfate interaction domain. J Biol Chem (2009) 284(41):28033-44. doi:10.1074/jbc. M109.035808
49. Tang R, Rosen SD. Functional consequences of the subdomain organization of the sulfs. J Biol Chem (2009) 284(32):21505-14. doi:10.1074/jbc. M109.028472
50. Uchimura K, Morimoto-Tomita M, Rosen SD. Measuring the activities of the Sulfs: two novel heparin/heparan sulfate endosulfatases. Methods Enzymol (2006) 416:243-53. doi:10.1016/S0076-6879(06)16015-2
51. Nagamine S, Keino-Masu K, Shiomi K, Masu M. Proteolytic cleavage of the rat heparan sulfate 6-O-endosulfatase SulfFP2 by furin-type proprotein convertases. Biochem Biophys Res Commun (2010) 391(1):107-12. doi:10.1016/j.bbrc.2009.11.011
52. Ambasta RK, Ai X, Emerson CP Jr. Quail Sulf1 function requires asparagine-linked glycosylation. J Biol Chem (2007) 282(47):34492-9. doi:10.1074/jbc. M706744200
53. Ai X, Do AT, Lozynska O, Kusche-Gullberg M, Lindahl U, Emerson CP Jr. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. J Cell Biol (2003) 162(2):341-51. doi:10.1083/jcb.200212083
54. Lamanna WC, Baldwin RJ, Padva M, Kalus I, Ten Dam G, van Kuppevelt TH, et al. Heparan sulfate 6-O-endosulfatases: discrete in vivo activities and functional co-operativity. Biochem J (2006) 400(1):63-73. doi:10.1042/BJ20060848
55. Seffouh A, Milz F, Przybylski C, Laguri C, Oosterhof A, Bourcier S, et al. HSulf sulfatases catalyze processive and oriented 6-O-desulfation of heparan sulfate that differentially regulates fibroblast growth factor activity. FASEB J (2013) 27(6):2431-9. doi:10.1096/fj.12-226373
56. Staples GO, Shi X, Zaia J. Glycomics analysis of mammalian heparan sulfates modified by the human extracellular sulfatase HSulf2. PLoS One (2011) 6(2):e16689. doi:10.1371/journal.pone.0016689
57. Viviano BL, Paine-Saunders S, Gasiunas N, Gallagher J, Saunders S. Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin. J Biol Chem (2004) 279(7):5604-11. doi:10.1074/jbc. M310691200
58. Pempe EH, Burch TC, Law CJ, Liu J. Substrate specificity of 6-O-endosulfatase (Sulf-2) and its implications in synthesizing anticoagulant heparan sulfate. Glycobiology (2012) 22(10):1353-62. doi:10.1093/glycob/cws092
59. Ai X, Kitazawa T, Do AT, Kusche-Gullberg M, Labosky PA, Emerson CP Jr. SULF1 and SULF2 regulate heparan sulfate-mediated GDNF signaling for esophageal innervation. Development (2007) 134(18):3327-38. doi:10.1242/dev.007674
60. Holst CR, Bou-Reslan H, Gore BB, Wong K, Grant D, Chalasani S, et al. Secreted sulfatases Sulf1 and Sulf2 have overlapping yet essential roles in mouse neonatal survival. PLoS One (2007) 2(6):e575. doi:10.1371/journal.pone.0000575
61. Kalus I, Salmen B, Viebahn C, von Figura K, Schmitz D, D'Hooge R, et al. Differential involvement of the extracellular 6-O-endosulfatases Sulf1 and Sulf2 in brain development and neuronal and behavioural plasticity. J Cell Mol Med (2009) 13(11-12):4505-21. doi:10.1111/j.1582-4934.2008.00558.x
62. Lamanna WC, Frese MA, Balleininger M, Dierks T. Sulf loss influences N-, 2-O-, and 6-O-sulfation of multiple heparan sulfate proteoglycans and modulates fibroblast growth factor signaling. J Biol Chem (2008) 283(41):27724-35. doi:10.1074/jbc. M802130200
63. Langsdorf A, Schumacher V, Shi X, Tran T, Zaia J, Jain S, et al. Expression regulation and function of heparan sulfate 6-O-endosulfatases in the spermatogonial stem cell niche. Glycobiology (2011) 21(2):152-61. doi:10.1093/glycob/cwq133
64. Lum DH, Tan J, Rosen SD, Werb Z. Gene trap disruption of the mouse heparan sulfate 6-O-endosulfatase gene, Sulf2. Mol Cell Biol (2007) 27(2):678-88. doi:10.1128/MCB.01279-06
65. Zhao W, Sala-Newby GB, Dhoot GK. Sulf1 expression pattern and its role in cartilage and joint development. Dev Dyn (2006) 235(12):3327-35. doi:10.1002/dvdy.20987
66. Nagamine S, Tamba M, Ishimine H, Araki K, Shiomi K, Okada T, et al. Organ-specific sulfation patterns of heparan sulfate generated by extracellular sulfatases Sulf1 and Sulf2 in mice. J Biol Chem (2012) 287(12):9579-90. doi:10.1074/jbc. M111.290262
67. Waldow A, Schmidt B, Dierks T, von Bulow R, von Figura K. Amino acid residues forming the active site of arylsulfatase A. Role in catalytic activity and substrate binding. J Biol Chem (1999) 274(18):12284-8. doi:10.1074/jbc.274.18.12284
68. Milz F, Harder A, Neuhaus P, Breitkreuz-KorffO, Walhorn V, Lubke T, et al. Cooperation of binding sites at the hydrophilic domain of cell-surface sulfatase Sulf1 allows for dynamic interaction of the enzyme with its substrate heparan sulfate. Biochim Biophys Acta (2013) 1830(11):5287-98. doi:10.1016/j.bbagen.2013.07.014
69. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, et al. HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem (2006) 7:2. doi:10.1186/1471-2091-7-2
70. Otsuki S, Hanson SR, Miyaki S, Grogan SP, Kinoshita M, Asahara H, et al. Extracellular sulfatases support cartilage homeostasis by regulating BMP and FGF signaling pathways. Proc Natl Acad Sci U S A (2010) 107(22):10202-7. doi:10.1073/pnas.0913897107
71. Dai Y, Yang Y, MacLeod V, Yue X, Rapraeger AC, Shriver Z, et al. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J Biol Chem (2005) 280(48):40066-73. doi:10.1074/jbc. M507986200
72. Lai J, Chien J, Staub J, Avula R, Greene EL, Matthews TA, et al. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem (2003) 278(25):23107-17. doi:10.1074/jbc. M302203200
73. Lai JP, Chien JR, Moser DR, Staub JK, Aderca I, Montoya DP, et al. hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology (2004) 126(1):231-48. doi:10.1053/j.gastro.2003.09.043
74. Li J, KleeffJ, Abiatari I, Kayed H, Giese NA, Felix K, et al. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer (2005) 4(1):14. doi:10.1186/1476-4598-4-30
75. Narita K, Staub J, Chien J, Meyer K, Bauer M, Friedl A, et al. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. Cancer Res (2006) 66(12):6025-32. doi:10.1158/0008-5472.CAN-05-3582
76. Yue X, Li X, Nguyen HT, Chin DR, Sullivan DE, Lasky JA. Transforming growth factor-beta1 induces heparan sulfate 6-O-endosulfatase 1 expression in vitro and in vivo. J Biol Chem (2008) 283(29):20397-407. doi:10.1074/jbc. M802850200
77. Danesin C, Agius E, Escalas N, Ai X, Emerson C, Cochard P, et al. Ventral neural progenitors switch toward an oligodendroglial fate in response to increased Sonic hedgehog (Shh) activity: involvement of sulfatase 1 in modulating Shh signaling in the ventral spinal cord. J Neurosci (2006) 26(19):5037-48. doi:10.1523/JNEUROSCI.0715-06.2006
78. Ma HY, Zhang F, Li J, Mo ML, Chen Z, Liu L, et al. HSulf-1 suppresses cell growth and down-regulates Hedgehog signaling in human gastric cancer cells. Oncol Lett (2011) 2(6):1291-5. doi:10.3892/ol.2011.407
79. Narita K, Chien J, Mullany SA, Staub J, Qian X, Lingle WL, et al. Loss of HSulf-1 expression enhances autocrine signaling mediated by amphiregulin in breast cancer. J Biol Chem (2007) 282(19):14413-20. doi:10.1074/jbc. M611395200
80. Langsdorf A, Do AT, Kusche-Gullberg M, Emerson CP Jr, Ai X. Sulfs are regulators of growth factor signaling for satellite cell differentiation and muscle regeneration. Dev Biol (2007) 311(2):464-77. doi:10.1016/j.ydbio.2007.08.053
81. Nakamura I, Fernandez-Barrena MG, Ortiz-Ruiz MC, Almada LL, Hu C, Elsawa SF, et al. Activation of the transcription factor GLI1 by WNT signaling underlies the role of SULFATASE 2 as a regulator of tissue regeneration. J Biol Chem (2013) 288(29):21389-98. doi:10.1074/jbc. M112.443440
82. Otsuki S, Taniguchi N, Grogan SP, D'Lima D, Kinoshita M, Lotz M. Expression of novel extracellular sulfatases Sulf-1 and Sulf-2 in normal and osteoarthritic articular cartilage. Arthritis Res Ther (2008) 10(3):R61. doi:10.1186/ar2432
83. Sala-Newby GB, George SJ, Bond M, Dhoot GK, Newby AC. Regulation of vascular smooth muscle cell proliferation, migration and death by heparan sulfate 6-O-endosulfatase1. FEBS Lett (2005) 579(28):6493-8. doi:10.1016/j.febslet.2005.10.026
84. Celie JW, Rutjes NW, Keuning ED, Soininen R, Heljasvaara R, Pihlajaniemi T, et al. Subendothelial heparan sulfate proteoglycans become major L-selectin and monocyte chemoattractant protein-1 ligands upon renal ischemia/reperfusion. Am J Pathol (2007) 170(6):1865-78. doi:10.2353/ajpath.2007.070061
85. Hassing HC, Mooij H, Guo S, Monia BP, Chen K, Kulik W, et al. Inhibition of hepatic sulfatase-2 in vivo: a novel strategy to correct diabetic dyslipidemia. Hepatology (2012) 55(6):1746-53. doi:10.1002/hep.25580
86. Yue X, Lu J, Auduong L, Sides MD, Lasky JA. Overexpression of Sulf2 in idiopathic pulmonary fibrosis. Glycobiology (2013) 23(6):709-19. doi:10.1093/glycob/cwt010
87. Blackhall FH, Merry CL, Davies EJ, Jayson GC. Heparan sulfate proteoglycans and cancer. Br J Cancer (2001) 85(8):1094-8. doi:10.1054/bjoc.2001.2054
88. Chen Z, Fan JQ, Li J, Li QS, Yan Z, Jia XK, et al. Promoter hypermethylation correlates with the Hsulf-1 silencing in human breast and gastric cancer. Int J Cancer (2009) 124(3):739-44. doi:10.1002/ijc.23960
89. Rosen SD, Lemjabbar-Alaoui H. Sulf-2: an extracellular modulator of cell signaling and a cancer target candidate. Expert Opin Ther Targets (2010) 14(9):935-49. doi:10.1517/14728222.2010.504718
90. Backen AC, Cole CL, Lau SC, Clamp AR, McVey R, Gallagher JT, et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br J Cancer (2007) 96(10):1544-8. doi:10.1038/sj.bjc.6603747
91. Bret C, Moreaux J, Schved JF, Hose D, Klein B. SULFs in human neoplasia: implication as progression and prognosis factors. J Transl Med (2011) 9:72. doi:10.1186/1479-5876-9-72
92. Hur K, Han TS, Jung EJ, Yu J, Lee HJ, Kim WH, et al. Up-regulated expression of sulfatases (SULF1 and SULF2) as prognostic and metastasis predictive markers in human gastric cancer. J Pathol (2012) 228(1):88-98. doi:10.1002/path.4055
93. Lui NS, van Zante A, Rosen SD, Jablons DM, Lemjabbar-Alaoui H. SULF2 expression by immunohistochemistry and overall survival in oesophageal cancer: a cohort study. BMJ Open (2012) 2(6):e001624. doi:10.1136/bmjopen-2012-001624
94. Nawroth R, van Zante A, Cervantes S, McManus M, Hebrok M, Rosen SD. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS One (2007) 2(4):e392. doi:10.1371/journal.pone.0000392
95. Morimoto-Tomita M, Uchimura K, Bistrup A, Lum DH, Egeblad M, Boudreau N, et al. Sulf-2, a proangiogenic heparan sulfate endosulfatase, is upregulated in breast cancer. Neoplasia (2005) 7(11):1001-10. doi:10.1593/neo.05496
96. Khurana A, Beleford D, He X, Chien J, Shridhar V. Role of heparan sulfatases in ovarian and breast cancer. Am J Cancer Res (2013) 3(1):34-45.
97. Yang JD, Sun Z, Hu C, Lai J, Dove R, Nakamura I, et al. Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival. Genes Chromosomes Cancer (2011) 50(2):122-35. doi:10.1002/gcc.20838
98. Khurana A, Liu P, Mellone P, Lorenzon L, Vincenzi B, Datta K, et al. HSulf-1 modulates FGF2-and hypoxia-mediated migration and invasion of breast cancer cells. Cancer Res (2011) 71(6):2152-61. doi:10.1158/0008-5472.CAN-10-3059
99. Lai JP, Sandhu DS, Moser CD, Cazanave SC, Oseini AM, Shire AM, et al. Additive effect of apicidin and doxorubicin in sulfatase 1 expressing hepatocellular carcinoma in vitro and in vivo. J Hepatol (2009) 50(6):1112-21. doi:10.1016/j.jhep.2008.12.031
100. Lai JP, Yu C, Moser CD, Aderca I, Han T, Garvey TD, et al. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology (2006) 130(7):2130-44. doi:10.1053/j.gastro.2006.02.056
101. Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, et al. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (2008) 47(4):1211-22. doi:10.1002/hep.22202
102. Lemjabbar-Alaoui H, van Zante A, Singer MS, Xue Q, Wang YQ, Tsay D, et al. Sulf-2, a heparan sulfate endosulfatase, promotes human lung carcinogenesis. Oncogene (2010) 29(5):635-46. doi:10.1038/onc.2009.365
103. Moussay E, Palissot V, Vallar L, Poirel HA, Wenner T, El Khoury V, et al. Determination of genes and microRNAs involved in the resistance to fludarabine in vivo in chronic lymphocytic leukemia. Mol Cancer (2010) 9:115. doi:10.1186/1476-4598-9-115
104. Peterson SM, Iskenderian A, Cook L, Romashko A, Tobin K, Jones M, et al. Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts. BMC Cancer (2010) 10:427. doi:10.1186/1471-2407-10-427
105. Sahota AP, Dhoot GK. A novel SULF1 splice variant inhibits Wnt signalling but enhances angiogenesis by opposing SULF1 activity. Exp Cell Res (2009) 315(16):2752-64. doi:10.1016/j.yexcr.2009.06.029
106. Zheng X, Gai X, Han S, Moser CD, Hu C, Shire AM, et al. The human sulfatase 2 inhibitor 2,4-disulfonylphenyl-tert-butylnitrone (OKN-007) has an antitumor effect in hepatocellular carcinoma mediated via suppression of TGFB1/SMAD2 and Hedgehog/GLI1 signaling. Genes Chromosomes Cancer (2013) 52(3):225-36. doi:10.1002/gcc.22022
107. Garteiser P, Doblas S, Watanabe Y, Saunders D, Hoyle J, Lerner M, et al. Multiparametric assessment of the anti-glioma properties of OKN007 by magnetic resonance imaging. J Magn Reson Imaging (2010) 31(4):796-806. doi:10.1002/jmri.22106
108. Hossain MM, Hosono-Fukao T, Tang R, Sugaya N, van Kuppevelt TH, Jenniskens GJ, et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology (2010) 20(2):175-86. doi:10.1093/glycob/cwp159
109. Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs (2008) 17(11):1769-76. doi:10.1517/13543784.17.11.1769
110. Schelwies M, Brinson D, Otsuki S, Hong YH, Lotz MK, Wong CH, et al. Glucosamine-6-sulfamate analogues of heparan sulfate as inhibitors of endosulfatases. Chembiochem (2010) 11(17):2393-7. doi:10.1002/cbic.201000401
111. Bond CS, Clements PR, Ashby SJ, Collyer CA, Harrop SJ, Hopwood JJ, et al. Structure of a human lysosomal sulfatase. Structure (1997) 5(2):277-89. doi:10.1016/S0969-2126(97)00185-8
112. Hernandez-Guzman FG, Higashiyama T, Pangborn W, Osawa Y, Ghosh D. Structure of human estrone sulfatase suggests functional roles of membrane association. J Biol Chem (2003) 278(25):22989-97. doi:10.1074/jbc. M211497200
113. Lukatela G, Krauss N, Theis K, Selmer T, Gieselmann V, von Figura K, et al. Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. Biochemistry (1998) 37(11):3654-64. doi:10.1021/bi9714924
114. Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell (2011) 147(5):992-1009. doi:10.1016/j.cell.2011.11.016
115. Iozzo RV, Sanderson RD. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 15(5):1013-31. doi:10.1111/j.1582-4934.2010.01236.x
116. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U. Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer (2002) 2(7):521-8. doi:10.1038/nrc842